US EditionPublished • loading... • Updated
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
- ImmVira announced promising interim efficacy data for MVR-T3011, showing high CR and RFS rates for BCG-unresponsive bladder cancer patients, according to Dr. Grace Zhou, Chairwoman and CEO of ImmVira.
- Bladder cancer is among the top 10 most common solid tumors globally, as reported by Frost & Sullivan, necessitating long treatment and surveillance periods.
- Current treatment for high-risk NMIBC is Bacillus Calmette-Guerin , but its availability is hindered by global supply shortages.
Insights by Ground AI
38 Articles
38 Articles
The Berkshire Eagle+37 Reposted by 37 other sources
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The…
Coverage Details
Total News Sources38
Leaning Left3Leaning Right6Center14Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
13%
C 61%
R 26%
Factuality
To view factuality data please Upgrade to Premium
